N-[4-(4-methoxyphenoxy)phenyl]acetamide | 873978-05-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[4-(4-methoxyphenoxy)phenyl]acetamide
• 英文别名: acetic acid-[4-(4-methoxy-phenoxy)-anilide]；4-Acetamino-1-(4-methoxy-phenoxy)-benzol；Essigsaeure-[4-(4-methoxy-phenoxy)-anilid]
• CAS: 873978-05-3
• 化学式: C₁₅H₁₅NO₃
• 分子量: 257.289
• InChiKey: MXPOICRVDKPNPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-[4-(4-methoxyphenoxy)phenyl]acetamide 在 barium dihydroxide 、 sodium dithionite 、 乙醇 、 硝酸 、 溶剂黄146 作用下， 生成 3,4-diamino-4'-methoxydiphenyl ether
  参考文献：
  名称：

  �ber Phenyl�ther

  摘要：

  DOI：

  10.1007/bf01522107
• 作为产物：
  描述：

  4-(4-硝基苯氧基)苯甲醚 在 铁粉 、 溶剂黄146 作用下， 生成 N-[4-(4-methoxyphenoxy)phenyl]acetamide
  参考文献：
  名称：

  �ber Phenyl�ther

  摘要：

  DOI：

  10.1007/bf01522107

文献信息

• Copper-Catalyzed One-Pot Multicomponent Coupling Reaction of Phenols, Amides, and 4-Bromphenyl Iodide
  作者：Wenming Chen、Jianjun Li、Dongmei Fang、Chun Feng、Chenggang Zhang

  DOI：10.1021/ol801730g

  日期：2008.10.16

  An efficient copper-catalyzed multicomponent reaction of phenols, amides, and 4-bromphenyl iodide was developed that uses commercially available N,N-dimethylglycine as the ligand. This multicomponent reaction proceeds in moderate to good yields for a range of phenols and amides. The simple experimental procedure and high levels of functional group compatibility make this method attractive for applications

  开发了一种有效的铜催化的酚，酰胺和4-溴苯基碘化物的多组分反应，该反应使用可商购的N，N-二甲基甘氨酸作为配体。对于多种酚和酰胺，该多组分反应以中等至良好的产率进行。简单的实验程序和高水平的官能团相容性使该方法对农药应用具有​​吸引力。
• Phenoxytacrine derivatives: Low-toxicity neuroprotectants exerting affinity to ifenprodil-binding site and cholinesterase inhibition
  作者：Anna Misiachna、Barbora Svobodova、Jakub Netolicky、Marketa Chvojkova、Lenka Kleteckova、Lukas Prchal、Martin Novak、Martina Hrabinova、Tomas Kucera、Lubica Muckova、Zuzana Moravcova、Jana Zdarova Karasova、Jaroslav Pejchal、Filip Blazek、David Malinak、Kristina Hakenova、Barbora Hrcka Krausova、Marharyta Kolcheva、Marek Ladislav、Jan Korabecny、Jens Pahnke、Karel Vales、Martin Horak、Ondrej Soukup

  DOI：10.1016/j.ejmech.2024.116130

  日期：2024.2

  pharmacodynamic studies. Finally, compound showing only minor affinity to AChE, was identified as a lead candidate with favorable behavioral and neuroprotective effects using open-field and prepulse inhibition tests, along with scopolamine-based behavioral and NMDA-induced hippocampal lesion models. Our data show that compound exhibits low toxicity often associated with NMDA receptor ligands, and low hepatotoxicity

  他克林（THA）是一种长期退役的药物，但由于其良好的反应活性和多靶点作用，仍然是药物化学中常用的支架。然而，THA 相关的肝毒性仍然是一个问题，在基于 THA 支架的药物发现中必须考虑这一问题。继我们之前鉴定的热门化合物 7-苯氧基他克林 (7-PhO-THA) 之后，我们系统地探索了 30 种新型衍生物的化学空间，重点关注低肝毒性、抗胆碱酯酶作用以及对 NMDA 受体 GluN1/GluN2B 亚型的拮抗作用。应用基于药代动力学数据的向下选择过程，两种候选药物以及由于与艾芬地尔结合位点相互作用而产生的选择性 GluN1/GluN2B 抑制剂已进入药效学研究。最后，通过开放场和预脉冲抑制测试以及基于东莨菪碱的行为和 NMDA 诱导的海马损伤模型，该化合物被确定为具有良好行为和神经保护作用的主要候选化合物。我们的数据表明，该化合物表现出低毒性，通常与 NMDA 受体配体相关，并且具有低肝毒性，通常与基于
• Genetic Population Structure and Origin of Life History Types in Chinook Salmon in British Columbia, Canada
  作者：David J. Teel、George B. Milner、Gary A. Winans、W. Stewart Grant

  DOI：10.1577/1548-8659(2000)129<0194:gpsaoo>2.0.co;2

  日期：2000.1

  We used protein electrophoresis to examine genetic population structure and origin of life history types of chinook salmon Oncorhynchus tshawytscha in British Columbia, Canada. Among 31 allozyme loci resolved in 91 samples from 63 populations of chinook salmon in rivers and hatcheries throughout British Columbia, population heterozygosities averaged 0.084 (range 0.048-0.108) and were typical of values for populations in other regions. A hierarchical gene diversity analysis indicated that 91.3% of the total allele-frequency diversity was attributable to within-population variability; the remaining 8.7% was attributable to geographic variability among populations, which was partitioned into among-river (3.3%), among-area (3.5%), and among-region (1.9%) components. Two major groups of populations appeared in the principal components analysis and in cluster analysis of genetic distances. A coastal group included populations in four subgroups: Central coast, Georgia Strait, lower Fraser River, and west Vancouver Island. An inland group included six subgroups: Nass River, Skeena River, north Thompson River, upper and mid-Fraser River, south Thompson River, and lower Thompson River. The geographic extents of the inland and coastal groups largely coincided with the geographic distributions of stream- and ocean-type juvenile forms and may reflect postglacial colonization by two ancestral lineages that survived in Pleistocene refugia. The presence of genetically undifferentiated stream-type fish in coastal streams populated by ocean-type fish may reflect either postglacial life history differentiation from ancestral ocean-type fish or life history flexibility of ocean-type fish.
• [EN] CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS<br/>[FR] DÉRIVÉS DE CAPRÉOMYCINE, ET LEUR UTILISATION EN TANT QU'AGENTS ANTIBACTÉRIENS
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2007130743A2

  公开（公告）日：2007-11-15

  [EN] The present invention relates to phenylurea derivatives of capreomycin I, IIB, IIA, or IB, and metabolites and pharmaceutically acceptable salts and solvates thereof. The compounds of the present invention are useful as antibacterial agents for treating bacterial infections and for treating disorders caused by bacterial infections. The present invention also relates to pharmaceutical compositions containing such compounds and to methods of treating bacterial infections by administering such compounds. The present invention also relates to methods of preparing such compounds.
  [FR] L'invention concerne des dérivés de phénylurée de capréomycine I, IIB, IIA, ou IB, ainsi que des métabolites, des sels pharmaceutiquement acceptables et des solvates de ces composés. Les composés selon l'invention peuvent servir d'agents antibactériens pour traiter des infections bactériennes, ainsi que pour traiter des troubles causés par des infections bactériennes. Cette invention se rapporte en outre à des compositions pharmaceutiques comprenant lesdits composés, ainsi qu'à des procédés pour traiter des infections bactériennes par administration de ces composés. La présente invention concerne en outre des procédés pour préparer lesdits composés.